Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Acquired | Acquired

About Lonza Biologics Tuas

Lonza Biologics Tuas was set-up in 2007 as joint venture between Lonza and Singapore government's Economic Development Board (EDB) as a large-scale cell culture manufacturing site for the production of monoclonal antibodies and recombinant proteins for biopharmaceuticals serving the pharmaceutical and biotechnology industries. Since 2009 it is a wholly owned company of Lonza Group.

Lonza Biologics Tuas Headquarter Location

35 Tuas South Ave 6

637377,

Singapore

+65 6521 4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Lonza Biologics Tuas Patents

Lonza Biologics Tuas has filed 220 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Cell biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/26/2019

11/16/2021

Sodium compounds, Oxidizing agents, Sulfates, Food additives, Excipients

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/26/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/16/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Sodium compounds, Oxidizing agents, Sulfates, Food additives, Excipients

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.